Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ximelagatran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 17/20 | 0.76 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MASP2 | O00187 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ximelagatran SCHEMBL14542684 | 1.00 | F2 (0.76) | F2PLATPRSS1F10ALDH1A1 | |
| SCHEMBL681225 | 0.93 | F2 (0.65) | F2PLATPRSS1F10ALDH1A1 | |
| SCHEMBL8083322 | 0.90 | F2 (0.78) | F2PLATPRSS1F10ALDH1A1 | |
| Ximelagatran SCHEMBL19065093 | 0.86 | F2 (1.00) | F2PLATPRSS1F10ALDH1A1 | |
| Ximelagatran SCHEMBL4845 | 0.86 | F2 (1.00) | F2PLATPRSS1F10ALDH1A1 | |
| Ximelagatran SCHEMBL14509860 | 0.86 | F2 (1.00) | F2PLATPRSS1F10ALDH1A1 | |
| Ximelagatran SCHEMBL15908919 | 0.86 | F2 (1.00) | F2PLATPRSS1F10ALDH1A1 | |
| SCHEMBL7217026 | 0.85 | F2 (0.76) | F2PLATPRSS1F10ALDH1A1 | |
| SCHEMBL6818264 | 0.85 | F2 (0.77) | F2PLATPRSS1F10ALDH1A1 | |
| SCHEMBL8130307 | 0.84 | F2 (0.54) | F2PLATPRSS1ALDH1A1MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487111-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| EP-2170877-B1 | SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION | BAYER IP GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-8198267-B2 | Substituted oxazolidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| EP-2167499-B1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20110003804-A1 | Oxazolidinones For the Treatment and/or Prophylaxis of Heart Failure | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| EP-2138178-A1 | Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009156082-A1 | OXAZOLIDINONES FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR ASTHMA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009074249-A1 | OXAZOLIDINONES FOR THE TREATMENT AND/OR PROPHYLAXIS OF HEART FAILURE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008155034-A1 | SUBSTITUTED OXAZOLIDINONES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155069-A2 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| US-20070111947-A1 | Fibrin targeted therapeutics | MCMURRY THOMAS J | 2007-05-17 | — | — | US | disclosed |
| US-20070111947-A1 | Fibrin targeted therapeutics | MCMURRY THOMAS J | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003804-A1 | Oxazolidinones For the Treatment and/or Prophylaxis of Heart Failure | SERPINC1, F11, XDH | F2 5/4885PLAT 23/4885PRSS1 416/4885 |
| US-20100298293-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, OXA1L, PPOX | F2 46/4885PLAT 66/4885PRSS1 3197/4885 |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | XDH, OXA1L, PPOX | F2 39/4885PLAT 81/4885PRSS1 3031/4885 |
| US-20100184740-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F2 30/4885PLAT 96/4885PRSS1 3275/4885 |
| US-20100261759-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE | XDH, MPL, OXA1L | F2 30/4885PLAT 96/4885PRSS1 3275/4885 |
| US-20070111947-A1 | Fibrin targeted therapeutics | FGB, F13B, F2 | F2 3/4885PLAT 5/4885PRSS1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.